These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 29650268)
21. Carfilzomib. Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635 [TBL] [Abstract][Full Text] [Related]
22. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ; Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818 [TBL] [Abstract][Full Text] [Related]
23. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245 [TBL] [Abstract][Full Text] [Related]
24. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Landgren O; Sonneveld P; Jakubowiak A; Mohty M; Iskander KS; Mezzi K; Siegel DS Leukemia; 2019 Sep; 33(9):2127-2143. PubMed ID: 31341235 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. Imtiaz H; Khan M; Ehsan H; Wahab A; Rafae A; Khan AY; Jamil A; Sana MK; Jamal A; Ali TJ; Ansar I; Khan MM; Khouri J; Anwer F Onco Targets Ther; 2021; 14():4941-4960. PubMed ID: 34629878 [TBL] [Abstract][Full Text] [Related]
26. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Dhakal B; Narra RK; Giri S; Szabo A; Smunt TL; Ghose S; Pathak LK; Aryal M; Hamadani M; Chhabra S; Janz S; D'Souza A; Hari PN Cancer; 2020 Jun; 126(12):2791-2801. PubMed ID: 32154922 [TBL] [Abstract][Full Text] [Related]
27. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. Sugiura I; Suzuki K; Ri M; Chou T; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Iida S Int J Hematol; 2020 Jan; 111(1):57-64. PubMed ID: 31664647 [TBL] [Abstract][Full Text] [Related]
28. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797 [TBL] [Abstract][Full Text] [Related]
29. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. Hobeika L; Self SE; Velez JC BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524 [TBL] [Abstract][Full Text] [Related]
30. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237 [TBL] [Abstract][Full Text] [Related]
31. Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis. Costa BA; Costa TA; Saravia SD; Felix N; Tan CR; Korde N; Richter J Am J Hematol; 2024 Jun; 99(6):1056-1065. PubMed ID: 38488702 [TBL] [Abstract][Full Text] [Related]
32. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421 [TBL] [Abstract][Full Text] [Related]
33. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437 [TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369 [TBL] [Abstract][Full Text] [Related]
35. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516 [TBL] [Abstract][Full Text] [Related]
36. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148 [TBL] [Abstract][Full Text] [Related]
37. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580 [TBL] [Abstract][Full Text] [Related]
38. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]